Boston Scientific Announces Results For 1st Quarter 2021.

MARLBOROUGH, Mass: Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational1 basis and 5.9 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $327 million or $0.23 per share (EPS), compared to GAAP net income of $11 million or $0.01 per share a year ago, and achieved adjusted EPS of $0.37 for the period, compared to $0.28 a year ago.

"We are pleased by the trajectory of our recovery," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "Our global team remains committed to helping patients and our customers by delivering a robust portfolio of innovative solutions, and that commitment will continue to fuel our future growth."

First quarter financial results and recent developments:

Reported net sales of $2.752 billion, representing an increase of 8.2 percent on a reported basis, compared to the company's guidance range of 0 to 6 percent; 5.6 percent on an operational basis; and 5.9 percent on an organic basis, compared to the company's guidance range of (3) to 3 percent, all compared to the prior year period.

Reported GAAP net income available to common stockholders of $0.23 per share compared to the company's guidance range of $0.05 to $0.11 per share. Achieved adjusted EPS of $0.37 compared to the guidance range of $0.28 to $0.34 per share.

Achieved net sales growth in each reportable segment4, compared to the prior year period:

MedSurg: 11.1 percent reported, 8.6 percent operational and 9.5 percent organic

Rhythm and Neuro: 6.8 percent reported, 4.0 percent operational and 1.6 percent organic

Cardiovascular: 10.0 percent reported, 7.4 percent operational and organic

Achieved the following regional5 net sales growth, compared to the prior year period:

U.S.: 8.6 percent reported and operational

EMEA (Europe, Middle East and Africa): 9.4 percent reported and 1.9 percent operational

APAC (Asia-Pacific): 15.6 percent reported and 9.1 percent operational

Emerging Markets3: 16.0 percent reported and 13.2 percent operational

Received U.S. Food and Drug Administration (FDA) approval for the TheraSphere Y-90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer, and secured FDA Breakthrough Device designation for...